Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): Targeting Pathomechanisms with Bruton Tyrosine Kinase Inhibitors

Abstract

A series of cases with rare thromboembolic incidents including cerebral sinus vein thrombosis (some of them fatal) and concomitant thrombocytopenia occurring shortly after vaccination with the coronavirus disease 2019 (COVID-19) vaccine AZD1222 (Vaxzevria) have caused significant concern and led to its temporary suspension in many countries. Immediate laboratory efforts in four of these patients have identified a tentative pathomechanism underlying this syndrome termed initially vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) and renamed recently vaccine-induced immune thrombotic thrombocytopenia (VITT). It encompasses the presence of platelet-activating antibodies to platelet factor-4/heparin complexes, possibly emulated by polyanionic constituents of AZD1222, and thus resembles heparin-induced thrombocytopenia (HIT). Because these immune complexes bind and activate platelets via Fcγ receptor IIA (FcγRIIA), high-dose intravenous immunoglobulin G has been suggested for treatment of VITT in addition to non-heparin anticoagulants. Here we propose inhibitors of Bruton tyrosine kinase (Btk) approved for B cell malignancies (e.g., ibrutinib) as another therapeutic option in VITT, as they are expected to pleiotropically target multiple pathways downstream of FcγRIIA-mediated Btk activation, for example, as demonstrated for the effective inhibition of platelet aggregation, dense granule secretion, P-selectin expression and platelet-neutrophil aggregate formation stimulated by FcγRIIA cross-linking. Moreover, C-type lectin-like receptor CLEC-2- and GPIb-mediated platelet activation, the interactions and activation of monocytes and the release of neutrophil extracellular traps, as encountered in HIT, could be attenuated by Btk inhibitors. As a paradigm for emergency repurposing of approved drugs in COVID-19, off-label use of Btk inhibitors in a low-dose range not affecting haemostatic functions could thus be considered a sufficiently safe option to treat VITT.

Keywords

COVID-19 vaccine - thrombocytopenia - platelet - Btk - FcγRIIA

Note

After acceptance of this review, two articles have been published which describe further cases of vaccine-induced thrombotic thrombocytopenia (VITT). See below:

1. Greinacher A, Thiele T, Warkentin TE, et al. Thrombotic thrombocytopenia after ChadOx1 nCoV-19 vaccination. N Engl J Med 2021;384(22):2092–2101

2. Schultz NH, Sørvoll IH, Michelsen AE, et al. Thrombosis and thrombocytopenia after ChadOx1 nCoV-19 vaccination. N Engl J Med 2021;384(22):2124–2130

^* The review process for this paper was fully handled by Gregory Y. H. Lip, Editor-in-Chief.

Publication History

Received: 06 April 2021

Accepted: 09 April 2021

Accepted Manuscript online:
13 April 2021

Article published online:
28 May 2021

• References

• 1 Mallapaty S, Callaway E. What scientists do and don't know about the Oxford-AstraZeneca COVID vaccine. Nature 2021; 592 (7852): 15-17
• 2 European Medicines Agency. Vaxzevria1 (Covid-19 vaccine (ChAdOx1-s [recombinant])). 2021 . Report No.: EMA/182334/2021, EMEA/H/C/005675. Available at: https://www.ema.europa.eu/en/documents/overview/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-medicine-overview_en.pdf
• 3 Paul-Ehrlich-Institut. Sehr seltene Fälle von Hirnvenenthrombosen nach Impfung. Paul Ehrlich Institut; 2021. . Available at: https://www.pei.de/DE/service/presse/aktuelles/aktuelles-inhalt.html;jsessionid=7C63F1E4F9A2A12E296611B36952A6F0.intranet2414
• 4 ARD. Hohe Impfquote: Großbritannien setzt weiter auf Astrazeneca. 2021 . Available at: https://www.ardmediathek.de/video/hohe-impfquote-grossbritannien-setzt-weiter-auf-astrazeneca/tagesschau24/Y3JpZDovL2Rhc2Vyc3RlLmRlL3RhZ2Vzc2NoYXUyNC85MTE3NDhlZC04NWU2LTRlMzUtODIxMy02NDI4ZGVlOWQ4ZDYvMQ/
• 5 UK.gov. Coronavirus vaccine: weekly summary of yellow card reporting. 2021 . Available at: https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting
• 6 European Medicines Agency. EMA confirms overall benefit-risk remains positive. News. 2021. Available at: https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood
• 7 Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle P, Eichinger S. A prothrombotic thrombocytopenic disorder resembling heparin-induced thrombocytopenia following coronavirus-19 vaccination. Research Square 2021; 1-8 . Available at: https://doi.org/10.21203/rs.3.rs-362354/v1
• 8 Greinacher A. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 2015; 373 (03) 252-261
• 9 Arepally GM. Heparin-induced thrombocytopenia. Blood 2017; 129 (21) 2864-2872
• 10 Zhang S, Liu Y, Wang X. et al. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. J Hematol Oncol 2020; 13 (01) 120
• 11 Almuqrin A, Davidson AD, Williamson MK. et al. SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription. Genome Med 2021; 13 (01) 43
• 12 Oda A, Ikeda Y, Ochs HD. et al. Rapid tyrosine phosphorylation and activation of Bruton's tyrosine/Tec kinases in platelets induced by collagen binding or CD32 cross-linking. Blood 2000; 95 (05) 1663-1670
• 13 Goldmann L, Duan R, Kragh T. et al. Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (FcγRIIA): a new option in HIT?. Blood Adv 2019; 3 (23) 4021-4033
• 14 Bond DA, Woyach JA. Targeting BTK in CLL: beyond ibrutinib. Curr Hematol Malig Rep 2019; 14 (03) 197-205
• 15 Treon SP, Castillo JJ, Skarbnik AP. et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood 2020; 135 (21) 1912-1915
• 16 Scarfò L, Chatzikonstantinou T, Rigolin GM. et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia 2020; 34 (09) 2354-2363
• 17 von Hundelshausen P, Siess W. Bleeding by Bruton tyrosine kinase-inhibitors: dependency on drug type and disease. Cancers (Basel) 2021; 13 (05) 1103
• 18 Busygina K, Jamasbi J, Seiler T. et al. Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation in humans. Blood 2018; 131 (24) 2605-2616
• 19 Busygina K, Denzinger V, Bernlochner I, Weber C, Lorenz R, Siess W. Btk inhibitors as first oral atherothrombosis- selective antiplatelet drugs?. Thromb Haemost 2019; 119 (08) 1212-1221
• 20 Tutwiler V, Madeeva D, Ahn HS. et al. Platelet transactivation by monocytes promotes thrombosis in heparin-induced thrombocytopenia. Blood 2016; 127 (04) 464-472
• 21 Thomas MR, Storey RF. The role of platelets in inflammation. Thromb Haemost 2015; 114 (03) 449-458
• 22 Chang BY, Huang MM, Francesco M. et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther 2011; 13 (04) R115
• 23 Gollomp K, Kim M, Johnston I. et al. Neutrophil accumulation and NET release contribute to thrombosis in HIT. JCI Insight 2018; 3 (18) 99445
• 24 Perdomo J, Leung HHL, Ahmadi Z. et al. Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia. Nat Commun 2019; 10 (01) 1322
• 25 Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton's tyrosine kinase in B cells and malignancies. Mol Cancer 2018; 17 (01) 57
• 26 Bikdeli B, Madhavan MV, Jimenez D. et al; Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function. Covid-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up—JACC state-of-the-art review. J Am Coll Cardiol 2020; 75 (23) 2950-2973
• 27 McFadyen JD, Stevens H, Peter K. The emerging threat of (micro)thrombosis in Covid-19 and its therapeutic implications. Circ Res 2020; 127 (04) 571-587
• 28 Aghagoli G, Gallo Marin B, Katchur NJ, Chaves-Sell F, Asaad WF, Murphy SA. Neurological involvement in Covid-19 and potential mechanisms: a review. Neurocrit Care 2020;
• 29 Yachou Y, El Idrissi A, Belapasov V, Ait Benali S. Neuroinvasion, neurotropic, and neuroinflammatory events of SARS-CoV-2: understanding the neurological manifestations in COVID-19 patients. Neurol Sci 2020; 41 (10) 2657-2669
• 30 Johnston I, Sarkar A, Hayes V. et al. Recognition of PF4-VWF complexes by heparin-induced thrombocytopenia antibodies contributes to thrombus propagation. Blood 2020; 135 (15) 1270-1280
• 31 Liu J, Fitzgerald ME, Berndt MC, Jackson CW, Gartner TK. Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo. Blood 2006; 108 (08) 2596-2603
• 32 Denzinger V, Busygina K, Jamasbi J. et al. Optimizing platelet GPVI inhibition versus hemostatic impairment by ibrutinib and the novel Btk-inhibitors acalabrutinib, ONO/GS-4059, BGB-3111 and evobrutinib. Thromb Haemost 2019; 119: 397-406
• 33 Kazianka L, Drucker C, Skrabs C. et al. Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib. Leukemia 2017; 31 (05) 1117-1122
• 34 Levade M, David E, Garcia C. et al. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood 2014; 124 (26) 3991-3995
• 35 Rayes J, Watson SP, Nieswandt B. Functional significance of the platelet immune receptors GPVI and CLEC-2. J Clin Invest 2019; 129 (01) 12-23
• 36 Nicolson PL, Welsh JD, Chauhan A, Thomas MR, Kahn ML, Watson SP. A rationale for blocking thromboinflammation in COVID-19 with Btk inhibitors. Platelets 2020; 31 (05) 685-690
• 37 Payne H, Ponomaryov T, Watson SP, Brill A. Mice with a deficiency in CLEC-2 are protected against deep vein thrombosis. Blood 2017; 129 (14) 2013-2020
• 38 Hitchcock JR, Cook CN, Bobat S. et al. Inflammation drives thrombosis after Salmonella infection via CLEC-2 on platelets. J Clin Invest 2015; 125 (12) 4429-4446
• 39 Nicolson PLR, Nock SH, Hinds J. et al. Low-dose Btk inhibitors selectively block platelet activation by CLEC-2. Haematologica 2021; 106 (01) 208-219
• 40 Arman M, Krauel K. Human platelet IgG Fc receptor FcγRIIA in immunity and thrombosis. J Thromb Haemost 2015; 13 (06) 893-908
• 41 Lhermusier T, van Rottem J, Garcia C. et al. The Syk-kinase inhibitor R406 impairs platelet activation and monocyte tissue factor expression triggered by heparin-PF4 complex directed antibodies. J Thromb Haemost 2011; 9 (10) 2067-2076
• 42 Zufferey A, Kapur R, Semple JW. Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP). J Clin Med 2017; 6 (02) 6
• 43 Miltiadous O, Hou M, Bussel JB. Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment. Blood 2020; 135 (07) 472-490
• 44 Braselmann S, Taylor V, Zhao H. et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther 2006; 319 (03) 998-1008
• 45 Series J, Ribes A, Garcia C. et al. Effects of novel Btk and Syk inhibitors on platelet functions alone and in combination in vitro and in vivo. J Thromb Haemost 2020; 18 (12) 3336-3351
• 46 Imbruvica. Highlights of prescribing information. 2020 . Available at: https://imbruvica.com/files/prescribing-information.pdf
• 47 Calquence. Highlights of prescribing information. 2020 . Available at: https://www.azpicentral.com/calquence/calquence.pdf
• 48 Brukinsa. Highlights of Prescribing Information. 2020 . Available at: https://www.brukinsa.com/prescribing-information.pdf
• 49 PMDA Japan. Velexbru (tirabrutinib). Japanese prescribing information. 2020 . Available at: https://www.pmda.go.jp/files/000237315.pdf